Gentium S.p. A announced the members of its new Board of Directors and the appointment of an Interim CEO. The new Board is comprised of seven members, who were elected at the recent ordinary meeting of shareholders. Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of Bellus Health Inc., Chairman of Picchio International and Prognomix Inc. Dr. Bellini is currently a Board member of Molson Coors Brewing Company and also serves as a Board member of the Government of Canada's Science Technology Innovation Council. Ms. Gigliola Bertogolio, formerly an audit partner at Reconta Ernst & Young (the Italian affiliate of Ernst & Young LLP), previous member of Gentium's Board of Directors from December 2004 to August 2009. Ms. Bertoglio will continue to chair the Audit Committee. Mr. Marco Codella, Chief Financial Officer of Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., previous member of Gentium's Board of Directors from June 2005 to August 2009. Dr. Glenn Cooper, previously served as Chairman and Chief Executive Officer of Indevus Pharmaceuticals, has held numerous executive level positions at drug development companies and various clinical and regulatory positions with Eli Lilly and Company. Dr. Cooper will chair the Compensation Committee. Dr. Laura Ferro, former President and Chief Executive Officer of Gentium S.p.A., previous Chairperson of Gentium's Board of Directors from 2001 to August 2009. Dr. Khalid Islam, former President and Chief Executive Officer of Arpida Ltd, has held various executive functions in Marion Merrell Dow and Hoechst Marion Roussel, has over 22 years experience in the biotechnology and pharmaceutical industries. Dr. Bobby W. Sandage, Jr., Executive Vice President for Endo Pharmaceuticals. In addition, Dr. Sandage held various positions at Indevus Pharmaceuticals, including Executive Vice President of Research and Development and Chief Scientific Officer. Dr. Sandage will chair the Scientific Oversight Committee. The Board of Directors has initiated a search for a new Chief Executive Officer to replace Dr. Laura Ferro and has appointed Dr. Khalid Islam as Interim CEO on a temporary and part-time basis. Dr. Islam brings extensive industry and regulatory experience to Gentium.

Gentium S.p.A, Annual General Meeting, Oct 15, 2009

Gentium S.p. A announced unaudited earnings results for the second quarter and six months ended June 30, 2009. For the quarter, the company reported net loss of €4.53 million or €0.30 per share on total revenue of €1.86 million compared to net loss of €0.49 million or €0.03 per share on total revenue of €2.61 million for the same period a year ago. Operating loss was €4.63 million compared to €0.41 million for the same period a year ago. Loss before income tax expense was €4.53 million compared to €0.49 million for the same period a year ago. For the six months, the company reported net loss of €10.61 million or €0.71 per share on total revenue of €4.55 million compared to net loss of €3.45 million or €0.23 per share on total revenue of €3.62 million for the same period a year ago. Operating loss was €9.48 million compared to €3.55 million for the same period a year ago. Loss before income tax expense was €10.61 million compared to €3.45 million for the same period a year ago. Net cash used in operating activities was €8.65 million compared to €9.31 million for the same period a year ago. Capital expenditures were €0.33 million compared to €0.25 million for the same period a year ago. The company reported that the difference in net loss was primarily due to lower research and development expenses, offset by an increase in higher margin from product sales through the named-patient program.